Inclusion Criteria:

1. Tumor type:

Metastatic or Locally Advanced Breast Cancer; Malignant Mesothelioma; Glioblastoma
Multiforme (Grade IV); Sarcoma's; Colorectal tumors or rare tumors (less than 500
patients a year)

2. Extent of disease:

- Metastatic Breast Cancer or High Risk Locally Advanced Breast Cancer

- Partial or Complete response after first line chemotherapy for both
metastatic or locally advanced breast cancer. Minimal metastatic disease
under hormonal treatment

- High risk Locally Advanced breast cancer defined as (and/or):

- Age < 60 years old

- ER, PR and Her-2 Neu negative tumors

- > 4 lymphnodes at initial presentation

- Mastitis Carcinomatosis

- Pregnancy associated Breast Cancer

- Malignant Mesothelioma:

- Partial or Complete response after first line chemotherapy not amendable
for surgery

- Adjuvant after debulking surgery

- Glioblastoma Multiforme

- In Recurrent Disease after optimal treatment according to Stupp regimen

- In primary disease after debulking surgery, Temodal/radiotherapy and
Temodal chemotherapy for 6 months

- Sarcoma's

- After adjuvant chemotherapy for uterine sarcoma's

- After Optimal or Debulking Surgery for liposarcoma's, synovial cell
sarcoma's

- Recurrent sarcoma's with limited disease

- Colorectal tumors

- K-ras wild-type tumors with inoperable lymphnode metastasis after standard
chemotherapy (FOLFOX, FOLFIRI)

3. Patient Characteristics

- Prior treatments: Patients must have received at least one prior
chemotherapeutic regimen and must be more than 1 month past the last treatment.

- Age: ≥ 18 years old

- Performance status: WHO PS grade 0-1 (Appendix B)

- Objectively assessable parameters of life expectancy: more than 3 months

- Prior and concomitant associated diseases allowed with the exception of
underlying autoimmune disease and positive serology for HIV/HBV/HCV

- No concomitant use of immunosuppressive drugs, hormonal treatment for breast
cancer is allowed in case of stable disease

- Adequate renal and liver function, i.e. creatinin and bilirubin = 1.2 times the
upper limit of normal

- Absence of any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the
trial

- Women of child-bearing potential should use adequate contraception prior to
study entry and for the duration of study participation

Exclusion Criteria:

1. Subjects with concurrent additional malignancy (with exception of non-melanoma skin
cancers and carcinoma in situ of the cervix)

2. Subjects who are pregnant

3. Subjects who have sensitivity to drugs that provide local anesthesia

4. Subjects needing corticosteroids 1 mg/kg during vaccination; corticosteroids are
allowed as part of their treatment when taken ≥ 30 days before the start of
vaccination.